Lapatinib‑induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro Corrigendum in /10.3892/or.2021.8074

Liao,Qiuyue; Feng,Xue; Li,Xi; Chen,Ge; Chen,Jing; Yang,Bin; Li,Kezhen; Ai,Jihui

doi:10.3892/or.2020.7660

Lapatinib‑induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro

Corrigendum in: /10.3892/or.2021.8074

Authors:
- Qiuyue Liao
- Xue Feng
- Xi Li
- Ge Chen
- Jing Chen
- Bin Yang
- Kezhen Li
- Jihui Ai
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: June 24, 2020 https://doi.org/10.3892/or.2020.7660
Pages: 1127-1135
Copyright: © Liao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study was designed to ascertain whether lapatinib, a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR), affects ovarian reserve and fertility potential in a mouse model. Female C57BL/6 mice were treated with either vehicle or lapatinib (100 or 200 mg/kg/day orally) for 4 weeks, after which body weight, vaginal smears, follicle numbers, serum anti‑Müllerian hormone (AMH) levels and mating outcomes were analyzed to assess the ovarian reserve and reproductive function. Slices from the ovaries of 4‑week‑old mice were cultured with lapatinib (0, 5 or 10 µM) for 24 and 48 h, and protein expression levels were assessed to validate the changes in signaling pathways. The results indicated that mice treated with 200 mg/kg lapatinib showed a slight decrease in body weight compared to those treated with vehicle or 100 mg/kg lapatinib. There was no statistical difference in estrous cyclicity among the three groups. No significant difference was observed in follicle numbers, AMH levels, histological morphologies of the ovaries or mating outcomes in the three groups of mice. Western blotting and immunohistochemical staining of the EGF receptor and its main downstream signaling pathways showed decreased phosphorylation of EGFR and mitogen‑activated protein kinase (MAPK)3/1 and increased phosphorylation of signal transducers and activators of transcription (STAT)3 in the lapatinib‑treated groups compared to the control group. Our study suggests that lapatinib has little effect on ovarian reserve and reproductive function in a mouse model. This lack of effect of lapatinib on ovarian function may be due to the activation of the STAT3 signaling pathway that counteracts the inhibitory effects of lapatinib on EGF receptors.

View Figures

View References

1	Johnson LN: Protein kinase inhibitors: Contributions from structure to clinical compounds. Q Rev Biophys. 42:1–40. 2009. View Article : Google Scholar : PubMed/NCBI
2	Dy GK and Adjei AA: Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 63:249–279. 2013. View Article : Google Scholar : PubMed/NCBI
3	Christopoulos C, Dimakopoulou V and Rotas E: Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med. 358:1079–1080. 2008. View Article : Google Scholar : PubMed/NCBI
4	Malozowski S, Nelson L and Calis KA: More on ovarian insufficiency with imatinib. N Engl J Med. 358:26482008. View Article : Google Scholar : PubMed/NCBI
5	Schultheis B, Nijmeijer BA, Yin H, Gosden RG and Melo JV: Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model. Leuk Res. 36:271–274. 2012. View Article : Google Scholar : PubMed/NCBI
6	Asadi-Azarbaijani B, Santos RR, Jahnukainen K, Braber S, van Duursen MBM, Toppari J, Saugstad OD, Nurmio M and Oskam IC: Developmental effects of imatinib mesylate on follicle assembly and early activation of primordial follicle pool in postnatal rat ovary. Reprod Biol. 17:25–33. 2017. View Article : Google Scholar : PubMed/NCBI
7	Sirotkin AV, Makarevich AV and Grosmann R: Protein kinases and ovarian functions. J Cell Physiol. 226:37–45. 2011. View Article : Google Scholar : PubMed/NCBI
8	Guo F, Kuo YF, Shih YCT, Giordano SH and Berenson AB: Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer. 124:3500–3509. 2018. View Article : Google Scholar : PubMed/NCBI
9	Richani D and Gilchrist RB: The epidermal growth factor network: Role in oocyte growth, maturation and developmental competence. Hum Reprod Update. 24:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
10	Conti M, Hsieh M, Park JY and Su YQ: Role of the epidermal growth factor network in ovarian follicles. Mol Endocrinol. 20:715–723. 2006. View Article : Google Scholar : PubMed/NCBI
11	Nagyova E, Nemcova L, Mlynarcikova A, Scsukova S and Kalous J: Lapatinib inhibits meiotic maturation of porcine oocyte-cumulus complexes cultured in vitro in gonadotropin-supplemented medium. Fertil Steril. 99:1739–1748. 2013. View Article : Google Scholar : PubMed/NCBI
12	Ma Z, Parris AB, Xiao Z, Howard EW, Kosanke SD, Feng X and Yang X: Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. J Exp Clin Cancer Res. 36:62017. View Article : Google Scholar : PubMed/NCBI
13	Spector NL, Robertson FC, Bacus S, Blackwell K, Smith DA, Glenn K, Cartee L, Harris J, Kimbrough CL, Gittelman M, et al: Lapatinib plasma and tumor concentrations and effects on HER receptor phosphorylation in tumor. PLoS One. 10:e01428452015. View Article : Google Scholar : PubMed/NCBI
14	Nelson JF, Felicio LS, Randall PK, Sims C and Finch CE: A longitudinal study of estrous cyclicity in aging C57BL/6J mice: I. Cycle frequency, length and vaginal cytology. Biol Reprod. 27:327–339. 1982. View Article : Google Scholar : PubMed/NCBI
15	Pedersen T and Peters H: Proposal for a classification of oocytes and follicles in the mouse ovary. J Reprod Fertil. 17:555–557. 1968. View Article : Google Scholar : PubMed/NCBI
16	Voigtlaender M, Schneider-Merck T and Trepel M: Lapatinib. Recent Results Cancer Res. 211:19–44. 2018. View Article : Google Scholar : PubMed/NCBI
17	da Rosa PRA, De Cesaro MP, Pereira Dau AM, Duggavathi R, Bordignon V and Gonçalves PBD: Reversible meiotic arrest of bovine oocytes by EGFR inhibition and follicular hemisections. Theriogenology. 99:53–62. 2017. View Article : Google Scholar : PubMed/NCBI
18	Ashkenazi H, Cao X, Motola S, Popliker M, Conti M and Tsafriri A: Epidermal growth factor family members: Endogenous mediators of the ovulatory response. Endocrinology. 146:77–84. 2005. View Article : Google Scholar : PubMed/NCBI
19	Fan HY, Liu Z, Shimada M, Sterneck E, Johnson PF, Hedrick SM and Richards JS: MAPK3/1 (ERK1/2) in ovarian granulosa cells are essential for female fertility. Science. 324:938–941. 2009. View Article : Google Scholar : PubMed/NCBI
20	Siddappa D, Beaulieu É, Gévry N, Roux PP, Bordignon V and Duggavathi R: Effect of the transient pharmacological inhibition of Mapk3/1 pathway on ovulation in mice. PLoS One. 10:e01193872015. View Article : Google Scholar : PubMed/NCBI
21	Su YQ, Denegre JM, Wigglesworth K, Pendola FL, O'Brien MJ and Eppig JJ: Oocyte-dependent activation of mitogen-activated protein kinase (ERK1/2) in cumulus cells is required for the maturation of the mouse oocyte-cumulus cell complex. Dev Biol. 263:126–138. 2003. View Article : Google Scholar : PubMed/NCBI
22	Sobinoff AP, Sutherland JM and Mclaughlin EA: Intracellular signalling during female gametogenesis. Mol Hum Reprod. 19:265–278. 2013. View Article : Google Scholar : PubMed/NCBI
23	Haraguchi S, Ikeda M, Akagi S and Hirao Y: Dynamic changes in pStat3 are involved in meiotic spindle assembly in mouse oocytes. Int J Mol Sci. 21:12202020. View Article : Google Scholar
24	Lee HS, Kim KH, Kim EY, Lee SY, Ko JJ and Lee KA: Obox4-silencing-activated STAT3 and MPF/MAPK signaling accelerate nuclear membrane breakdown in mouse oocytes. Reproduction. 151:369–378. 2016. View Article : Google Scholar : PubMed/NCBI
25	Tscherner A, Brown AC, Stalker L, Kao J, Dufort I, Sirard MA and LaMarre J: STAT3 signaling stimulates miR-21 expression in bovine cumulus cells during in vitro oocyte maturation. Sci Rep. 8:115272018. View Article : Google Scholar : PubMed/NCBI
26	Zulkifli AA, Tan FH, Putoczki TL, Stylli SS and Luwor RB: STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. Mol Cell Endocrinol. 451:15–23. 2017. View Article : Google Scholar : PubMed/NCBI
27	Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, et al: Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 12:28–36. 2013. View Article : Google Scholar : PubMed/NCBI
28	Haura EB, Sommers E, Song L, Chiappori A and Becker A: A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol. 5:1806–1814. 2010. View Article : Google Scholar : PubMed/NCBI
29	Li Q, Zhang D, Chen X, He L, Li T, Xu X and Li M: Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer. Sci Rep. 5:160822015. View Article : Google Scholar : PubMed/NCBI
30	Bonner JA, Yang ES, Trummell HQ, Nowsheen S, Willey CD and Raisch KP: Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother Oncol. 99:339–343. 2011. View Article : Google Scholar : PubMed/NCBI
31	Dowlati A, Nethery D and Kern JA: Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther. 3:459–463. 2004.PubMed/NCBI
32	Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE and Grandis JR: Targeting stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res. 18:4986–4996. 2012. View Article : Google Scholar : PubMed/NCBI
33	Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh MY, Horne D, Dellinger TH, Han ES, Jove R and Yim JH: Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Mol Cancer. 14:1002015. View Article : Google Scholar : PubMed/NCBI
34	Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and Settleman J: Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 26:207–221. 2014. View Article : Google Scholar : PubMed/NCBI